Posted on

Clearmind Medicine Inc. Retains Edge Communications Group for Investor Relations and Announces Granting of Stock Options

Clearmind Medicine Inc. Retains Edge Communications Group for Investor Relations and Announces Granting of Stock Options

Toronto, Ontario–(Newsfile Corp. – July 2, 2021) – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and under-served health problems, today announced that it has retained Edge Growth Holdings Corporation (“Edge Communications Group” or “Edge“) for strategic investor relations and capital markets communications services (the “Agreement“).

Clearmind CEO Gadi Levin stated, “We have been following Edge closely and have been consistently impressed by their innovation in the investor relations space. We feel that our company story will resonate particularly well with their target demographic, and we are excited to begin a professional relationship that we feel will benefit our shareholders.”

Edge is a team of capital markets communications professionals with a specific focus on engaging the millennial and gen z investor demographic. Edge will provide Clearmind a full spectrum communications strategy that combines traditional investor communications with new age platforms such as Instagram, TikTok, Discord & Reddit.

Under the terms of the Agreement, Clearmind will pay Edge Communications Group a monthly fee of CAD $10,000 for ongoing strategic communication services. In addition, Kevan Matheson will receive 100,000 stock options with an exercise price of $0.84 that vest after 4 months and have a term of two years. The Agreement is for an initial term of four months. At the time of this announcement, neither Edge Communications Group, nor any of its executives have an ownership interest, directly or indirectly, in Clearmind or its securities.

Additionally, the Company wishes to announce that in accordance with the terms of the Company’s stock option plan it has granted a total of 800,000 options (the “Options“), with an exercise price of $0.84, of which 600,000 options were issued to directors and officers and the remainder, 200,000 options, to consultants of the Company. The Options shall vest in twelve (12) equal quarterly installments over a 36-month period, with one twelfth of the Options vesting at the end of each quarter with the first vesting on October 1st, 2021.

http://edgecommunicationsgroup.com

About Clearmind Medicine Inc.

Clearmind is a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic derived therapeutics to solve widespread and under-served health problems including alcohol use disorder. Its primary objective is to research and develop compounds derived from psychedelics and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of two patent families, one for binge behavior regulators and the other for an alcoholic beverage substitute. Within these two families the Company has two U.S. patents, one European patent, and allowed applications in China and India and pending divisional applications in Europe and the US related to binge behavior regulators; and a European patent and pending applications in the US, China and India related to the alcohol beverage substitute family.

For further information, please contact:

Investor Relations Contact
Email: invest@clearmindmedicine.com
Telephone: (778) 400-5347
www.Clearmindmedicine.com

For other inquiries
Info@Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing into early stage companies inherently carries a high degree of risk and investment into securities of the Company shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Not for distribution to U.S. newswire services or dissemination in the United States.

Posted on

Clearmind Medicine Inc. Announces Closing of Previously Announced Private Placements for Aggregate Gross Proceeds of CAD$6.225 Million at CAD $0.75 per Unit

Clearmind Medicine Inc. Announces Closing of Previously Announced Private Placements for Aggregate Gross Proceeds of CAD$6.225 Million at CAD $0.75 per Unit

Toronto, Ontario–(Newsfile Corp. – June 30, 2021) – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and under-served health problems, today announced that (further to its press releases of May 27, 2021, and June 20, 2021) that it has closed its previously announced private placement (the “Offering“) for an aggregate amount of $6,225,000 (the “Gross Proceeds“). The Offering resulted in the issuance of an aggregate of 8,300,000 units of the Company (“Units“) at a price of $0.75 per Unit. Each Unit consisted of one common share of the Company (“Common Share“) and one common share purchase warrant (“Warrant“), with each Warrant being exercisable to acquire one additional Common Share of the Company (a “Warrant Share“) at an exercise price of $1.25 per Warrant Share until December 30, 2022.

Cleramind Medicine CEO, Gadi Levin, said, “We are extremely pleased to have the continued support of the investment community. This financing is critical to the fast-growing psychedelic medicine industry. Clearmind Medicine is committed to develop solutions for the millions suffering from mental illness and addiction globally.”

Net proceeds from the Offering will be mainly used by the Company for the implementation of its R&D plan.

Common Shares and Warrants issued pursuant to the Offering will be subject to a statutory hold period, expiring on October 31, 2021, in accordance with applicable securities legislation.

The Company paid finder’s fees in association with this financing, payable in cash, of up to 10% of the Gross Proceeds.

About Clearmind Medicine Inc.

Clearmind is a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic derived therapeutics to solve widespread and under-served health problems including alcohol use disorder. Its primary objective is to research and develop compounds derived from psychedelics and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of two patent families, one for binge behavior regulators and the other for an alcoholic beverage substitute. Within these two families the Company has two U.S. patents, one European patent, and allowed applications in China and India and pending divisional applications in Europe and the US related to binge behavior regulators; and a European patent and pending applications in the US, China and India related to the alcohol beverage substitute family.

For further information, please contact:

Investor Relations
Contact – Edge Communications Group
Email: invest@clearmindmedicine.com
Telephone: (778) 400-5347

For other inquiries
Info@Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing into early-stage companies inherently carries a high degree of risk and investment into securities of the Company shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Offering have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Not for distribution to U.S. newswire services or dissemination in the United States.

Posted on

Clearmind Medicine Inc. Announces Increase to Previously Announced Non-Brokered Private Placement

Clearmind Medicine Inc. Announces Increase to Previously Announced Non-Brokered Private Placement

Toronto, Ontario–(Newsfile Corp. – June 20, 2021) – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and under-served health problems, today announced that, further to its press release of May 27, 2021, it intends to increase its previously announced private placement from gross proceeds of $6,000,000 to a maximum of up to $6,225,000 (the “Gross Proceeds“) by way of a non-brokered private placement (the “Private Placement“). The Private Placement will now consist of a maximum of up to 8,300,000 units of the Company (“Units“) at a price of $0.75 per Unit. Each Unit will consist of one common share of the Company (“Common Share“) and one common share purchase warrant (“Warrant“), with each Warrant being exercisable to acquire one Common Share of the Company (a “Warrant Share“) at an exercise price of $1.25 per Warrant Share for a period of eighteen (18) months following the closing of the Private Placement. Insiders of the Company may participate in the Private Placement in an amount equal to 20% of the Private Placement.

The Company anticipates that the Private Placement will close on or about June 30, 2021. Net proceeds from the Private Placement will be mainly used by the Company for the implementation of its R&D plan.

Common Shares and Warrants issued pursuant to the Private Placement will be subject to a statutory hold period of four months plus one day from the date of issuance, in accordance with applicable securities legislation.

The Company expects to pay finder’s fees in association with this financing, payable in cash, of up to 10% of the Gross Proceeds, or alternatively a combination of cash in an amount equal to 5% of the Gross Proceeds and that number of Finder Warrants as is equal to 5% of the Units sold (“Finder Warrants“). Each Finder Warrant will be exercisable into a Common Share (each a “Finder Share“) at an exercise price of $1.00 per Finder Share for a period of eighteen (18) months following the closing of the Private Placement.

About Clearmind Medicine Inc.

Clearmind is a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic derived therapeutics to solve widespread and under-served health problems including alcohol use disorder. Its primary objective is to research and develop compounds derived from psychedelics and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of two patent families, one for binge behavior regulators and the other for an alcoholic beverage substitute. Within these two families the Company has two U.S. patents, one European patent, and allowed applications in China and India and pending divisional applications in Europe and the US related to binge behavior regulators; and a European patent and pending applications in the US, China and India related to the alcohol beverage substitute family.

For further information, please contact:

Info@Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing into early stage companies, inherently carries a high degree of risk and investment into securities of the Company shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Not for distribution to U.S. newswire services or dissemination in the United States.

Posted on

Clearmind Medicine Inc. Announces Non-Brokered Private Placement and Granting of Stock Options

Clearmind Medicine Inc. Announces Non-Brokered Private Placement and Granting of Stock Options

Toronto, Ontario–(Newsfile Corp. – May 27, 2021) – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and under-served health problems, today announced that it intends to raise a minimum of $3,750,000 and a maximum of up to $6,000,000 (the “Gross Proceeds“) by way of a non-brokered private placement (the “Private Placement“). The Private Placement will consist of a minimum of 5,000,000 and a maximum of up to 8,000,000 units of the Company (“Units“) at a price of $0.75 per Unit. Each Unit will consist of one common share of the Company (“Common Share“) and one common share purchase warrant (“Warrant“), with each Warrant being exercisable to acquire one Common Share of the Company (a “Warrant Share“) at an exercise price of $1.25 per Warrant Share for a period of eighteen (18) months following the closing of the Private Placement. Insiders of the Company may participate in the Private Placement. Insiders of the Company may participate in the Private Placement in an amount equal to 20% of the Private Placement.

The Company anticipates that the Private Placement will close on or about June 15, 2021. Net proceeds from the Private Placement will be mainly used by the Company for the implementation of its R&D plan.

Common Shares and Warrants issued pursuant to the Private Placement will be subject to a statutory hold period of four months plus one day from the date of issuance, in accordance with applicable securities legislation.

The Company expects to pay finder’s fees in association with this financing, payable in cash, of up to 10% of the Gross Proceeds, or alternatively a combination of cash in an amount equal to 5% of the Gross Proceeds and that number of Finder Warrants as is equal to 5% of the Units sold (“Finder Warrants“). Each Finder Warrant will be exercisable into a Common Share (each a “Finder Share“) at an exercise price of $1.00 per Finder Share for a period of eighteen (18) months following the closing of the Private Placement.

Additionally, the Company wishes to announce that in accordance with the terms of the Company’s stock option plan it has granted a total of 2,350,000 options (the “Options“), with an exercise price of $0.75, of which 300,000 options were issued to directors and officers and the remainder to consultants of the Company. 133,333 of the Options, issued to consultants, shall vest immediately and the remainder of the Options shall vest in twelve (12) equal quarterly installments over a 36-month period, with one twelfth of the Options vesting at the end of each quarter with the first vesting on August 31, 2021.

About Clearmind Medicine Inc.

Clearmind is a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic derived therapeutics to solve widespread and under-served health problems including alcohol use disorder. Its primary objective is to research and develop compounds derived from psychedelics and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of two patent families, one for binge behavior regulators and the other for an alcoholic beverage substitute. Within these two families the Company has two U.S. patents, one European patent, and allowed applications in China and India and pending divisional applications in Europe and the US related to binge behavior regulators; and a European patent and pending applications in the US, China and India related to the alcohol beverage substitute family.

For further information, please contact:
Info@Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing into early stage companies, inherently carries a high degree of risk and investment into securities of the Company shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Not for distribution to U.S. newswire services or dissemination in the United States.

Posted on

Cyntar Ventures Inc. Completes Change of Business Listing as it Shifts Focus to Psychoactive Pharmaceuticals for Underserved Health Issues Under the Name Clearmind Medicine Inc.

Cyntar Ventures Inc. Completes Change of Business Listing as it Shifts Focus to Psychoactive Pharmaceuticals for Underserved Health Issues Under the Name Clearmind Medicine Inc.

Initial Emphasis On The Development Of Treatments For Disorders Related To Alcohol Use

Toronto, Ontario–(Newsfile Corp. – May 25, 2021) –  Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), today announced it has completed all requirements of the Canadian Securities Exchange (the “CSE” or the “Exchange“) for a Change of Business (“COB“) listing. Formerly Cyntar Ventures Inc, the Company is shifting from a mineral resource exploration operation to the research and development of innovative psychedelic therapeutics.

The Company first announced the COB in September 2020, in conjunction with the acquisition of all rights, title, and interest in several patents and patent applications for treatment of alcohol abuse disorder and various other non-controlled binge behaviors by Ezekiel Golan, now the Company’s Chief Scientific Officer and a Director.

Mr. Golan commented on the announcement, “Psychedelics as a class of pharmaceuticals have the potential to provide transformational solutions for people suffering from a number of mental-health disorders, including depression, addiction and alcohol abuse. These conditions can be emotionally and financially devastating for patients, their families and society as a whole. I am excited to be a part of the Clearmind team and look forward to working together to bring novel therapies from the lab to the clinic and eventually to patients.”

There is growing evidence that the FDA is slowly easing restrictions on psychedelic pharmaceuticals. Although they have only recently approved the first cannabis-based pharmaceutical, there are currently more than 600 cannabis related clinical trials on file with the National Institutes of Health (NIH). In 2019, the FDA granted the first Breakthrough Therapy designation (an expedited process for drugs where preliminary clinical evidence demonstrated a substantial improvement over available therapies for serious or life-threatening diseases) to two psilocybin-based drugs for the treatment of Major Depressive Disorder, and the NIH lists 64 psilocybin-based studies.

According to the NIH, approximately 6% of the US adult population (over 13 million people) had Alcohol Use Disorder in 2018. The financial burden on the country is in excess of $250 billion annually. Worldwide, it’s estimated that 5% of all deaths – approximately 3 million people — are attributable to alcohol consumption.

Gadi Levin, Clearmind’s Chief Executive Officer concluded, “This listing is a significant milestone for the Company and our investors. The new name and structure facilitate management’s ability to pursue opportunities in the emerging psychedelic pharmaceutical sector. Our first priority will be furthering our research related to the treatment of Alcohol Use Disorder; longer term we will explore solutions for other underserved conditions.”

Update on Outstanding Securities

As previously announced on April 16 and April 22, 2021 the Company completed several private placements. The following table sets out the current issued and outstanding securities of Clearmind (on a fully diluted basis):

SecurityAuthorizedOutstanding
Common Shares
(non-diluted basis)		Unlimited29,225,000
Stock Options10% of the issue and outstanding
Common Shares		480,000
Warrants7,500,0007,500,000
Common Shares
(fully diluted)		Unlimited37,685,000

‍

Available Funds

As a result of its two most recent financings Clearmind has a working capital of approximately $1,500,000 and a 12-month budget for research and development of $480,000. After removing overhead charges, the Issuer has approximately $722,000 in unallocated funds.

About Clearmind Medicine Inc.

Clearmind is a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic derived therapeutics to solve widespread and under-served health problems including alcohol use disorder. Its primary objective is to research and develop compounds derived from psychedelics and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of two patent families, one for binge behavior regulators and the other for an alcoholic beverage substitute. Within these two families the Company has two U.S. patents, one European patent, and allowed applications in China and India and pending divisional applications in Europe and the US related to binge behavior regulators; and a European patent and pending applications in the US, China and India related to the alcohol beverage substitute family.

The Listing Statement, which includes the change of the Company name from Cyntar Ventures Inc. to Clearmind Medicine Inc., has been posted on the CSE website www.thecse.com.

Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND” and will commence trading on May 26, 2021.

About Ezekel Golan

Mr. Golan is a multidisciplinary inventor in the fields of mycology, genetics, pharmacology, and behavioral neuroscience. He is the registered inventor of dozens of granted patents in these fields. Mr. Golan has been working in the pharmaceutical industry since 2002, in both scientific and management positions. In 2014 New Scientist Magazine called him “arguably the world’s most productive discoverer of designer drugs”.

For further information, please contact:
Info@Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators, and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing into early stage companies, inherently carries a high degree of risk and investment into securities of the Company shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.